SEC Form 4 · accession 0001179110-18-008573
Kala Pharmaceuticals, Inc. · KALA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Langer
Director
Period of report
Jun 12, 2018
Accepted (ET)
Jun 15, 2018 · 10:50 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479419
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.73 | Jun 12, 2018 | A | 12,960 | A | — | Jun 11, 2028 | Common Stock | 12,960 | 12,960 | D |
Explanation of responses
- F1This option was granted on June 12, 2018 and vests in equal monthly installments until the one-year anniversary of the date of grant and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.